Edition:
United States

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

81.36USD
23 Apr 2018
Change (% chg)

$1.96 (+2.47%)
Prev Close
$79.40
Open
$80.02
Day's High
$81.39
Day's Low
$79.93
Volume
243,076
Avg. Vol
320,362
52-wk High
$92.98
52-wk Low
$41.78

Chart for

About

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-re... (more)

Overall

Beta: 0.32
Market Cap(Mil.): $7,136.64
Shares Outstanding(Mil.): 89.88
Dividend: --
Yield (%): --

Financials

  NBIX.OQ Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -1.63 -- --
ROI: -25.97 -0.74 13.21
ROE: -41.50 -2.80 15.01

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Apr 10 2018

UPDATE 2-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Apr 10 2018

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Apr 10 2018

CORRECTED-UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Apr 10 2018

CORRECTED-FDA extends review for AbbVie, Neurocrine's uterine pain drug

April 10 AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Apr 10 2018

BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain

April 10 Abbvie And Neurocrine Biosciences Announce Pdufa Target Date Of Q3 2018 For Elagolix In Endometriosis :

Apr 10 2018

BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data

* NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSON'S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA

Feb 14 2018

BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07

* NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018

Feb 13 2018

BRIEF-Neurocrine Biosciences Presents Long-Term Data Analyses From Open-Label Kinect 4 Phase III Study

* NEUROCRINE BIOSCIENCES PRESENTS LONG-TERM DATA ANALYSES FROM OPEN-LABEL KINECT 4 PHASE III STUDY DEMONSTRATING INGREZZA® IMPROVES TARDIVE DYSKINESIA SYMPTOMS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Neurocrine Biosciences appoints Matt Abernethy as CFO

* Neurocrine Biosciences appoints Matt Abernethy as chief financial officer

Nov 20 2017

Earnings vs. Estimates